Dominic D'Agostino on Ketogenic Therapy, Ketone Supplements, and Hyperbaric Oxygen for Brain Injury
Dom D'Agostino returns to STEM-Talk to unpack 20+ new papers on ketogenic metabolic therapy for cancer, ketone supplement safety, and HBOT for TBI.
Riepilogo
Researcher Dominic D'Agostino joins STEM-Talk to discuss his lab's latest work on ketogenic metabolic therapy (KMT), ketone supplementation safety, and hyperbaric oxygen therapy. KMT — a high-fat, very low-carb diet keeping carbs under 20–25 grams per day — is being explored as a complement to immune-based cancer treatments, especially for aggressive brain tumors like glioblastoma. D'Agostino also covers a rodent study showing that different ketone supplement formulations have strikingly different effects on liver health: ketone salts appear protective, while some ketone esters and precursors may drive liver inflammation and fatty changes. Additionally, a proposed orthomolecular protocol aims to simultaneously enhance mitochondrial function and cut off cancer's two primary fuel sources — glucose and glutamine — targeting both cancer stem cells and metastasis.
Riepilogo Dettagliato
Ketogenic metabolic therapy has moved well beyond weight loss and epilepsy management. Dominic D'Agostino's lab at the University of South Florida has spent the past several years building a rigorous scientific case for using KMT alongside conventional and immune-based cancer treatments — work that has produced more than 20 papers since 2023 and positions dietary intervention as a serious adjunct in oncology.
The most urgent application is glioblastoma, the deadliest primary brain tumor in adults. D'Agostino co-authored a 49-author clinical research framework proposing that glioblastoma be managed through the lens of cancer as a metabolic and mitochondrial disease. The framework calls for aggressive patient education about KMT alongside standard therapies, reflecting a view that metabolic context matters as much as genetic targeting in high-grade gliomas.
A complementary paper on the mitochondrial stem cell connection (MSCC) theory argues that cancer originates when chronic oxidative phosphorylation insufficiency transforms stem cells into cancer stem cells. The proposed orthomolecular protocol aims to enhance oxidative phosphorylation while simultaneously blocking glucose and glutamine — described in the paper as cancer's two primary fuels — to target both cancer stem cells and metastasis.
On supplementation, a rodent study from D'Agostino's group revealed that not all ketone products are created equal. Ketone salts preserved liver health across chronic dosing, while certain ketone esters and precursors produced signs of liver inflammation and steatosis. This formulation-dependent divergence has significant implications for the rapidly growing consumer ketone supplement market, where long-term hepatic safety data have been largely absent.
The episode also touches on a February co-authored study with Ben Bikman (a previous STEM-Talk guest) and on hyperbaric oxygen therapy for traumatic brain injury. Caveats include reliance on rodent models for hepatic findings and the early-stage nature of KMT cancer protocols in humans.
Risultati Principali
- KMT combined with immune-based therapies shows promise for glioblastoma when carbs are kept under 20–25g/day.
- Ketone salts appear to preserve liver health in rodents; some ketone esters and precursors may cause liver inflammation and steatosis.
- The MSCC theory proposes cancer begins with mitochondrial dysfunction in stem cells, fueling abnormal metabolism.
- An orthomolecular protocol targeting both glucose and glutamine aims to cut cancer's primary fuels simultaneously.
- A 49-author clinical framework calls for aggressive patient education on KMT as adjunct glioblastoma care.
Metodologia
Key hepatic safety findings come from a rodent study evaluating multiple ketone supplement formulations at two dose levels, examining liver histopathology, inflammatory signaling, and systemic biomarkers. The cancer framework work is a large multi-author clinical review rather than a controlled trial. The podcast format draws on D'Agostino's lab publications but does not present primary data directly.
Limitazioni dello Studio
Summary is based on podcast show notes and abstract only, not a peer-reviewed paper; full episode content may contain additional nuance. Hepatic safety data are from rodent models and may not translate directly to human dosing. KMT cancer protocols remain largely investigational and have not yet been validated in large randomized controlled trials.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: